Key Drivers
- Strong Liquidity
- Rising Leverage
- Persistent Losses
AIAI Summary
ZBIO is now a catalyst-driven commercialization bet: the accepted obexelimab BLA and May 2027 PDUFA de-risk the path to approval, but its ~$1.9B valuation already demands successful specialist uptake in IgG4-RD and supportive SLE data, making approval without a strong label or launch outlook vulnerable to disappointment.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Rising Leverage
- •Persistent Losses
ZBIO has strong liquidity but faces escalating debt, heavy losses, cash burn, dilution, and an expensive valuation unsupported by current revenue.
Price Behavior
Key Price Behavior Insights:
- •Range-bound weakness
- •Support holding
- •Resistance overhead
ZBIO was range-bound to slightly weaker over the last month, with $31.10–$31.20 support intact but caution warranted unless it reclaims $32.90–$33.10 resistance.
Sharp drop from $33.05 to $31.10 in two trading days
Sentiment & News
Key News Insights:
- •Investor presentations
- •Obexelimab focus
- •Institutional buying
Zenas BioPharma is intensifying investor engagement around obexelimab while Bank of America's increased stake signals institutional interest, though no new clinical data were disclosed.
The news is modestly positive for ZBIO sentiment but lacks near-term clinical or financial catalysts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings